Brought to you by 
Cardio3 BioSciences SA acquires OnCyte LLC from Celdara Medical LLC
22 Sep 2020
Executive Summary
Cardio3 BioSciences SA (cell therapies) acquired OnCyte LLC (immuno-oncology) from Celdara Medical LLC for $182mm including earn-outs. Cardio3 paid $10mm up front ($6mm in cash and $4mm in stock) along with developmental and sales milestones up to $172mm plus a tiered 5-8% sales royalty.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cardio3 BioSciences SA acquires OnCyte LLC from Celdara Medical LLC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice